Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung

Current oncology

C. Roesel¹  K. Kambartel² 

[1] Bethanien Hospital Moers;Lung Cancer Center, Bethanien Hospital

关键词: Sarcomatoid carcinoma;    lung cancer;    immunotherapy;    PD-L1 expression;   

DOI  :  10.3747/co.26.4377

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Pulmonary sarcomatoid carcinoma (psc) is a rare subtype of non-small-cell lung carcinoma with a poor prognosis and poor response to chemotherapy and radiotherapy. A previous study reported that psc expresses high levels of PD-L1, suggesting the potential efficacy of immune checkpoint inhibitors in these tumours. We report 2 cases of patients with a lung sarcomatoid carcinoma. Both patients initially underwent curative lung resection, but developed early recurrent disease. Because PD-L1 was highly expressed in the tumour cells, we initiated therapy with nivolumab, which showed good efficacy, almost complete radiologic tumour remission, and a remarkable improvement in the condition of those patients. Immune checkpoint inhibitors targeting PD-1 might be a valuable therapy option for pscs.

【 授权许可】

Unknown